September 2020 Cancer Epidemiology Matters E-News

Cancer Epidemiology Matters E-News


Single IRB Policies for NIH Grantees Coordinating Multi-Site Research

More than half of the grants in the Epidemiology and Genomics Research Program's (EGRP) portfolio fall under NIH's Policy on the Use of a Single Institutional Review Board (sIRB) for Multi-Site Research and the Revised Common Rule's Cooperative Research Provision. The NIH policy, which went into effect on January 25, 2018, established the expectation that all domestic sites participating in multi-site studies will use an sIRB. If the NIH funds even one site in an applicable multi-site study (also referred to as cooperative research), the NIH expects all other sites using the same protocol will rely on a single IRB. Additionally, as of January 20, 2020, the revised Common Rule requires all institutions in the United States engaged in cooperative research conducted or supported by a Common Rule agency to use an sIRB for research conducted in the U.S.

Ongoing, non-competing awards are not expected to follow the NIH policy until the grantee submits a competing renewal application after the effective date (January 2018), and ancillary studies to other ongoing studies will not be expected to comply until the parent study is expected to comply.

Goals of the sIRB

The goal of sIRB is to enhance and streamline the IRB review process for multi-site research so that research can proceed as quickly as possible without compromising ethical principles and protections for human research participants.

IRB Models

IRB models that would meet the policy:

  1. Existing IRB can agree to serve as sIRB (Awardee or participating site)
  2. Independent/Unaffiliated IRB
  3. Central IRB organized to review specific projects (e.g., NCI Central IRB)

Exceptions

With the implementation of the revised Common Rule in January 2020, exceptions to the cooperative research provision of the revised Common Rule must be requested through the Office for Human Research Protections, U.S. Department of Health and Human Services (OHRP@HHS.gov). Current Common Rule exceptions for NIH-supported or -conducted cooperative research are where

NIH can only consider requests for exceptions to the NIH policy and not the Common Rule requirements. All exceptions granted by NIH continue to be site-specific, that is, the exception to single IRB review is only made for a particular site, with all other sites conducting the same protocol needing to rely on the single IRB.

Exceptions to the NIH policy are automatic when local IRB review is required by federal, tribal, or state law/regulation/policy. The specific law/regulation/policy should be cited in the grant application/contract proposal's single IRB plan. Exceptions will only be made for the site(s) affected by the state law/regulation/policy; other sites not affected by the state law/regulation/policy will be expected to rely on the single IRB.

Further Resources

Funding Opportunities & Notices of Special Interest

  • NOSI: Advancing the Science of Geriatric Palliative Care (NOT-AG-20-041)
  • NOSI: Research in the Emergency Setting (NOT-NS-20-005)
  • Tobacco Control Policies to Promote Health Equity (R01, R21, Clinical Trial Optional)
  • Genomic Data Analysis Network: Genomic Data Center (U24, Clinical Trial Not Allowed)
  • Cancer Intervention and Surveillance Modeling Network (CISNET) Incubator Program for New Cancer Sites (U01, Clinical Trial Not Allowed)
  • Centers to Advance Research in Endometriosis (CARE) (P01, Clinical Trial Not Allowed)
  • Glioblastoma Therapeutics Network (U19, Clinical Trial Required)
  • Core Infrastructure Support for Cancer Epidemiology Cohorts (U01, Clinical Trial Not Allowed)
  • Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01, Clinical Trial Required)
  • All of Us Research Program - National, State, and Local Engagement Partner Funding Opportunity (OT2)
  • The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00, Clinical Trial Not Allowed)
  • NCI Research Specialist Award
    • Core-based Scientist (R50, Clinical Trial Not Allowed)
    • Laboratory-based Scientist (R50, Clinical Trial Not Allowed)
    • NCI Clinical and Translational Exploratory/Developmental Studies (R21, Clinical Trial Optional)
  • Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01, Clinical Trial Optional)

Policy & General Notices

  • Policy for Charging Personal Protective Equipment to NIH Grants and Cooperative Agreements as Direct Costs (NOT-OD-20-164)
  • Reminder: NIH Natural Disaster Policy - Hurricane Laura (NOT-OD-20-172)
  • Reminder: NIH Natural Disaster Policy - Hurricane Isaias, Derecho (NOT-OD-20-161)
  • Reminder: NIH Natural Disaster Policy - Wildfires (NOT-OD-20-176)
  • Reissue of Parent Research Supplements to Promote Diversity in Health-Related Research FOA in October 2020 (NOT-OD-20-170)
  • Reminder: NIH Policy on Use of Hypertext in NIH Grant Applications (NOT-OD-20-174)
  • Changes to the HHS Notice of Award (NoA) Beginning October 1, 2020 (NOT-HS-20-017)

NIH News and Blog Posts

Stay Connected

Subscribe for Updates

Subscribe
You can subscribe and unsubscribe at any time by entering your email address and selecting your preferences on the page that follows.

Subscribe to the E-Newsletter

Follow Us on Twitter

Need Help?

EGRP staff can answer questions on grant funding, policies, and research resources. If you do not know who to contact we will do our best to connect you with someone who can help you.

Email Us
(240) 276-6730